Zosano Pharma, a Californian developer of the ZP transdermal patch technology, has hired Donald Kellerman as Vice President, Clinical Development; David Zhang as Executive Director, Biostatistics and Data Management; and Jacquie Mardell as Senior Director, Clinical Operations.
Thorsten von Stein, Chief Medical Officer of Zosano, said the three of them are 'great additions to our clinical and regulatory teams as we prepare to significantly advance our clinical-stage programmes for the treatment of osteoporosis, hypoglycaemia and migraine'.
Kellerman was most recently Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Prior to this, he was Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals (acquired by Allergan).
He was also Senior Vice President of Development at Inspire Pharmaceuticals, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. In addition, he has led groups responsible for running several clinical programmes in the respiratory, ophthalmology and cardiovascular areas. In addition, he has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor and E R Squibb and Sons.
Zhang joins Zosano from Genentech, where during a 13-year career he worked in clinical development across all phases in multiple therapeutic areas and geographic regions.
Prior to joining Genentech, Zhang worked at Eli Lilly and at Abbott Laboratories.
Mardell joins Zosano after serving for more than a year as clinical operations consultant for Zosano. She previously held clinical operations director positions at Metabolex (now Cymabay), Corcept Therapeutics, Neuromed Pharmaceuticals, Roche and Syntex, in a wide variety of therapeutic areas.
